New therapy against the bacterial enemy
TetramCOL® was developed from TetramOX by improving the membrane penetration into the pathogens. Based on the pharmacophore, which has been optimized for ten years, a new first-in-class active compound was developed that is currently in preclinical development and shows the following characteristics:
First in-class patented compound with new chemical structure (not a “me-too” or analog) that addresses exactly the problem of multi drug resistance.
Good potency and spectrum against important bacterial pathogens:
- E. coli is most common in community-acquired infections, including Urinary tract infections (UTIs), caused by extended-spectrum β-lactamase (ESBL)-producing E. coli
- Klebsiella pneumonia is another important gram-negative pathogen causing life threatening Neonatal sepsis
- Pseudomonas aeruginosa causes Pneumonia associated with cystic fibrosis, which is particularly severe in immunocompromised and AIDS patients
Innovative mode of action (UPPS), affecting the bacterial fat synthesis, with clear ID of the active center and low potential for resistance development
Excellent safety and compatibility with good therapeutic window, no genotoxicity, no phototoxicity, no cross resistance and other important positive characteristics
Good formulation features compound can be given orally and/or injected
Cost efficient and easy production allows reasonable pricing
Pre-clinical optimization is currently ongoing and first in-vivo data is expected by the end of 2021. The data will provide a clear understanding of the therapeutic potential of the compound. In parallel the team is carrying out further bio-activity analysis against important bacteria such as Salmonella typhi, Neisseria gonorrhoeae and Acinetobacter baumanii.
Oxford Antibiotic Group 